Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

This study has been completed.
Information provided by:
UCB Pharma Identifier:
First received: September 8, 2005
Last updated: November 14, 2013
Last verified: September 2009

The safety and efficacy of L059 will be evaluated in patients who completed "N165 Clinical Trial of L059". They will receive L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs

Condition Intervention Phase
Epilepsy, Partial
Drug: levetiracetam
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

Resource links provided by NLM:

Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • Frequency of AE/ADR

Secondary Outcome Measures:
  • Seizures frequency per week

Estimated Enrollment: 97
Study Start Date: September 2001
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both

Inclusion Criteria:

  1. Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059
  2. Patients/the parent or guardian wish to continue treatment with L059 and to enter N165 Follow-up Study, and also the investigator admit the necessity of the repeated intake of the investigational drug for the patients.

Exclusion Criteria:

  1. Patients who had not participate in N165 Clinical Trial of L059.
  2. Patients who had participated in N165 Clinical Trial of L059 with no intention of entering the follow-up study taking the same medication.
  3. Patients had not been in compliance with requirements of Protocol for N165 Clinical Trial of L059 in the course of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00160615

Sponsors and Collaborators
UCB Pharma
Study Director: UCB Clinical Trial Call Center UCB Pharma
  More Information

Additional Information:
No publications provided Identifier: NCT00160615     History of Changes
Other Study ID Numbers: N01020, L05/EPI/LG1/FN/01
Study First Received: September 8, 2005
Last Updated: November 14, 2013
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by UCB Pharma:
Epilepsy, Partial,
Keppra, levetiracetam

Additional relevant MeSH terms:
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Agents
Neuroprotective Agents
Nootropic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses processed this record on November 25, 2014